Teva Appeals In Delhi High Court To Block Natco’s Export Of Glatiramer
This article was originally published in PharmAsia News
Executive Summary
Teva’s petition to stop Natco from exporting glatiramer was dismissed by the Delhi High in February. The company has now appealed to a double bench in its continued efforts to prove that Natco’s move to export the compound infringes its international patents.
You may also be interested in...
Supreme Court Copaxone Case May Weaken Federal Circuit Review Of Patent Claims
Teva has a chance to block generic competition until Sept. 1, 2015; high court declines to hear False Claims Act case against Takeda and a challenge to Allergan’s Combigan patent.
Indian Government Denies Patent Application For Copaxone; Natco Pharma Says Obstacles Removed For Supply Of Generic Version Worldwide
MUMBAI - In a decision that could trigger a bigger battle, the Indian Patent Office has denied a patent application filed by an Israeli company for Copaxone(glatiramer), an innovative drug used in the treatment of multiple sclerosis
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.